WVE · Wave Life Sciences Ltd.

This redomiciliation represents a foundational structural shift for Wave Life Sciences, moving its ultimate parent company from Singapore to Delaware — a jurisdiction with well-established corporate governance frameworks, deeper capital markets access, and alignment with the company’s operational reality: its Nasdaq listing, U.S.-based headquarters in Cambridge, MA, majority of R&D and manufacturing facilities, and U.S.-dominant management and board. The Implementation Agreement formalizes a statutory scheme of arrangement under Singapore’s Companies Act, requiring both shareholder approval and sanction by the Singapore High Court — conditions that are not waivable per the agreement. The one-for-one share exchange preserves equity ownership economics and ensures continuity of trading under the same ticker (WVE) on Nasdaq, minimizing market disruption. Strategic rationale centers on administrative efficiency and cost reduction — specifically eliminating dual financial reporting, regulatory, legal, and compliance burdens arising from a Singapore parent overseeing U.S.-centric operations. While described as tax-free to U.S. shareholders, the agreement explicitly contemplates a U.S. Tax Election (Form 8832) to treat the Singapore entity as a disregarded entity post-closing, underscoring careful U.S. tax structuring. Completion is targeted for mid-2026 but remains subject to approvals and cannot extend beyond December 31, 2026. Investors should monitor the forthcoming definitive proxy statement for voting details, risk disclosures, and updated timing — particularly given forward-looking statements acknowledging material uncertainties around court and shareholder approval, potential delays, and unanticipated costs.